Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

Brandon Kulengowski; Justin A. Clark; David S. Burgess

doi:10.1016/j.diagmicrobio.2018.10.020

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

Brandon Kulengowski
, Justin A. Clark
, David S. Burgess

Pharmacy Practice and Science

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

Original language	English
Pages (from-to)	372-375
Number of pages	4
Journal	Diagnostic Microbiology and Infectious Disease
Volume	93
Issue number	4
DOIs	https://doi.org/10.1016/j.diagmicrobio.2018.10.020
State	Published - Apr 2019

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

Funding

We would like to acknowledge Julie A. Ribes, MD, PhD, and the UK HealthCare microbiology laboratory for their assistance in collection and testing of isolates. We also thank Sang Usayaporn, PharmD, and our pharmacy students/residents Matthew Brignola, Chanah K. Gallagher, J. Emery McVicar, Zachary J. Haffler, Chase N. Ayres, Eric R. Gregory, Aidan Sturgill, and Thien-Nam T. To for excellent technical assistance. This material is, in part, the result of work supported with resources and use of facilities at the Lexington, KY, VA Medical Center. The data and results of this study were presented at ASM Microbe 2018. Poster: AAR04-528. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declarations of interest: none.

Funders	Funder number
Durham VA Medical Center	AAR04-528

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Amikacin
Carbapenem-resistant Enterobacteriaceae
Meropenem
Polymyxin B
Time kill

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2018.10.020

Cite this

@article{c8aef5264e5e4c1590b5e28140ac43cf,

title = "Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin",

abstract = "Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.",

keywords = "Amikacin, Carbapenem-resistant Enterobacteriaceae, Meropenem, Polymyxin B, Time kill",

author = "Brandon Kulengowski and Clark, \{Justin A.\} and Burgess, \{David S.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.diagmicrobio.2018.10.020",

language = "English",

volume = "93",

pages = "372--375",

number = "4",

}

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin. / Kulengowski, Brandon; Clark, Justin A.; Burgess, David S.
In: Diagnostic Microbiology and Infectious Disease, Vol. 93, No. 4, 04.2019, p. 372-375.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

AU - Kulengowski, Brandon

AU - Clark, Justin A.

AU - Burgess, David S.

PY - 2019/4

Y1 - 2019/4

N2 - Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

AB - Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

KW - Amikacin

KW - Carbapenem-resistant Enterobacteriaceae

KW - Meropenem

KW - Polymyxin B

KW - Time kill

UR - https://www.scopus.com/pages/publications/85057473215

UR - https://www.scopus.com/pages/publications/85057473215#tab=citedBy

U2 - 10.1016/j.diagmicrobio.2018.10.020

DO - 10.1016/j.diagmicrobio.2018.10.020

M3 - Article

C2 - 30514595

AN - SCOPUS:85057473215

SN - 0732-8893

VL - 93

SP - 372

EP - 375

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

ER -

Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this